Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

Rhea-AI Summary

Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) held its Annual General and Special Meeting on June 2, 2025, where shareholders approved all proposed items. All six board nominees were successfully elected with high approval rates, led by James A. Helliwell and Joseph Freedman with 99.997% votes in favor. Shareholders also approved the appointment of KPMG LLP as auditors, the 2025 Omnibus Incentive Plan, and the re-pricing of certain non-executive employee stock options. Eupraxia is advancing its DiffuSphere™ technology platform, designed for targeted drug delivery with extended-release capabilities. The company has two key clinical programs: EP-104GI in Phase 1b/2a for EoE treatment and EP-104IAR, which recently completed a successful Phase 2b trial for knee osteoarthritis pain, meeting its primary endpoint and three secondary endpoints.

VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 2, 2025.

Pursuant to a resolution passed by ballot vote, all of the six nominees proposed by management for election to the Company’s board of directors (the “Board”) at the Meeting and listed in the Company’s Management Information Circular dated April 25, 2025, were elected. The directors will remain in office until the next annual meeting of shareholders, or until their successors are elected or appointed.

The results of the vote on the election of the Board are as follows:

Board of Directors	Votes in Favour		Votes Withheld
	Number of Votes	Percentage (%)	Number of Votes	Percentage (%)
James A. Helliwell	17,880,699	99.997	505	0.003
Simon Pimstone	16,123,679	90.171	1,757,475	9.829
Richard M. Glickman	17,879,949	99.993	1,255	0.007
Paul Geyer	17,680,609	98.878	200,595	1.122
John Montalbano	17,876,501	99.974	4,703	0.026
Michael Wilmink	17,876,508	99.974	4,696	0.026
Joseph Freedman	17,880,699	99.997	505	0.003

The other items of business at the Meeting were to (i) re-appoint KPMG LLP as the auditor of the Company for the ensuing year and to authorize the Board to fix the remuneration of the auditors; (ii) approve the Company’s 2025 Omnibus Incentive Plan; and (iii) approve the re-pricing of certain stock options previously granted to certain non-executive employees, none of which are insiders of the Company, under the Company’s amended and restated stock option plan. All such items of business were passed by the shareholders at the Meeting.

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.

Notice Regarding Forward-looking Statements and Information

This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", “suggests”, "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements in this news release include statements regarding the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company’s products, and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy its our product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the potential impact of tariffs on the cost of the Company’s API and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:
Danielle Egan, Eupraxia Pharmaceuticals Inc.
778.401.3302
degan@eupraxiapharma.com

or

Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com

SOURCE Eupraxia Pharmaceuticals Inc.

FAQ

What were the voting results for Eupraxia Pharmaceuticals (EPRX) 2025 annual meeting?

All six board nominees were elected with strong approval rates, with James A. Helliwell and Joseph Freedman receiving the highest support at 99.997% votes in favor. Shareholders also approved KPMG as auditors, the 2025 Omnibus Incentive Plan, and stock option re-pricing for non-executive employees.

What is Eupraxia's DiffuSphere technology and how does it work?

DiffuSphere is a polymer-based micro-sphere technology designed for targeted drug delivery with extended duration. It aims to provide precise targeting of tissues, potentially reducing adverse events through stable drug delivery compared to traditional methods.

What clinical trials is Eupraxia Pharmaceuticals (EPRX) currently conducting?

Eupraxia is conducting a Phase 1b/2a RESOLVE trial for EP-104GI in EoE treatment and recently completed a successful Phase 2b SPRINGBOARD trial for EP-104IAR in knee osteoarthritis pain.

Who are the key board members elected at Eupraxia's 2025 annual meeting?

The elected board members include James A. Helliwell, Simon Pimstone, Richard M. Glickman, Paul Geyer, John Montalbano, Michael Wilmink, and Joseph Freedman, with approval rates ranging from 90.171% to 99.997%.